Abstract
Combined LAG-3 and PD-1 blockade is an emerging strategy for the treatment of melanoma. Tawbi etal. and Amaria etal. report in The New England Journal of Medicine and Nature respectively on two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic, and resectable, high-risk, node-positive melanoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have